Salivary Toxicity from PSMA-Targeted Radiopharmaceuticals in mCRPC

Guest: Geoffrey B. Johnson, M.D., Ph.D. When looking at patients who suffer from prostate cancer who are receiving PSMA therapy, we can see on our images that the medication not only goes to their cancer, but it also goes to some other things in their body, including the salivary glands. To learn more about his recent study on salivary toxicity, join Dr. Geoffrey Johnson, Nuclear Medicine Specialist and Radiologist at the Mayo Clinic in Rochester, Minnesota.